The current status of chemoprevention in FAP: Commentary

Familial Cancer

Volumn 5, Issue 3, 2006, Pages 295-296

  Burn, J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APC PROTEIN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; STARCH;

ADENOMATOUS POLYP; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER SURGERY; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON RESECTION; COLORECTAL CANCER; DIET THERAPY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; FAMILIAL CANCER; GENE MUTATION; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL; SOMATIC MUTATION; TREATMENT DURATION;

EID: 33749038872     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-005-5660-8     Document Type: Note

References (1)

1. J. Burn 2003 Results of the CAPP1 study: Aspirin and resistant starch are beneficial in FAP Familial Cancer 2 Suppl 1 42